Close Menu

NEW YORK – Illumina reported after the close of the market on Thursday that its third quarter 2019 revenues grew 6 percent year over year.

For the three months ended Sept. 29, 2019, Illumina recorded total revenues of $907 million compared to $853 million a year ago, driven by a 12 percent growth in sequencing sales that was offset by a 24 percent decline in microarray revenues.

The company's Q3 revenues beat the consensus Wall Street estimate of $870.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
22
Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
29
Sponsored by
Illumina

“If we build it, they will come” is a familiar refrain that echoes in life science entrepreneurial circles. Too frequently startups believe that if a technology is built it will sell.